Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02285920 · ClinicalTrials.gov registry record · Phase 2
Safety and Cardiovascular Efficacy of Spironolactone in Dialysis-Dependent ESRD Trial
A Phase 2 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 2
- Development phase
- 129
- Enrollment target
NCT02285920: Completed Phase 2 study, sponsored by University of Pennsylvania.
NCT02285920 is a Phase 2 study that has completed, run by University of Pennsylvania. The registered enrollment target is 129 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02285920, a Phase 2 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 129 participants
- Enrollment target
Study Summary
The SPin-D Trial is a phase II randomized, double-blind, placebo-controlled, multi-center study of spironolactone (SPL) for patients with hemodialysis-dependent end-stage renal disease.
Interventions
- DRUG Spironolactone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2014-11 |
| Est. Completion | 2017-07-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02285920
The ClinicalTrials.gov registry entry for NCT02285920 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 129 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Spironolactone is the first listed.
NCT02285920 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02285920 about?
NCT02285920 is a clinical study titled "Safety and Cardiovascular Efficacy of Spironolactone in Dialysis-Dependent ESRD Trial". The SPin-D Trial is a phase II randomized, double-blind, placebo-controlled, multi-center study of spironolactone (SPL) for patients with hemodialysis-dependent end-stage renal disease.
What is the current status of trial NCT02285920?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 129 participants. The study started on 2014-11. Estimated completion is 2017-07-30.
What interventions are being tested in trial NCT02285920?
The interventions under investigation include: Spironolactone (DRUG).
Who is sponsoring clinical trial NCT02285920?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.